桂枝茯苓胶囊辅助治疗子宫内膜异位症对内膜厚度及血液流变学指标影响

Effects of Guizhi fuling capsule for adjuvant treating patients with endometriosis on their endometrial thickness and hemorheological indexes

目的:分析桂枝茯苓胶囊辅助治疗对子宫内膜异位症(EMS)对患者子宫内膜厚度及血液流变学影响。方法:选择2019年2月-2022年2月本院接诊的113例EMS患者,依照治疗方案不同分为对照组(米非司酮治疗,n=52)和中西医组(米非司酮+桂枝茯苓胶囊治疗,n=61),对比两组临床症状恢复、子宫内膜厚度、血液流变学指标、炎性指标、血清血管内皮生长因子(VEGF)、肿瘤相关抗原(CA125)水平及预后情况。结果:治疗后中西医组症状缓解(93.4%)及疼痛缓解(86.9%)均高于对照组(78.9%、76.9%),月经恢复时间(31.6±3.6d)短于对照组(37.4±4.9 d),子宫内膜厚度(2.42±0.50cm)小于对照组(3.35±0.67cm),痛经VAS评分(2.57±1.21分)低于对照组(3.94±1.10分),肿瘤坏死因子-α水平(89.32±5.46 ng/L)低于对照组(107.83±8.19 ng/L),白细胞介素-2(73.21±7.15 ng/L)、白细胞介素-10(94.71±9.86 ng/L)水平均高于对照组(68.55±6.30 ng/L、88.55±8.18 ng/L);治疗后两组血浆黏度、红细胞比积、红细胞沉降率均降低,两组VEGF、CA125水平均下降,且中西医组上述各指标下降程度高于对照组;中西医组复发(6.6%)、合并不孕症(8.2%)比例均低于对照组(21.2%、26.9%)(均P<0.05),不良反应两组无差异(P>0.05)。结论:桂桂枝茯苓胶囊辅助治疗EMS可缓解症状,改善子宫内膜厚度及血液流变学指标,调节炎性因子。

Objective:To analyze the effects of Guizhifuling capsulefor adjuvant treating patients with endometriosis(EMS)on their endometrial thickness and hemorheology.Methods:113 patients with EMS who were admitted to thehospital were selected and were divided into two groups according to the treatment plan from February 2019 to Febru-ary 2022.52 patients in the control group were given treatment of mifepristone and 61 patients in the experimentalgroup were given treatment of mifepristone combined with Guizhi fuling capsule,The recovery of clinical symptoms,the endometrial thickness,the dysmenorrhea,the indicators of hemorheology and inflammatory,the levels of serumvascular endothelal growth factor(VEGF)and tumor associated antigen(CA125),and the prognosis of the patientswere compared between the two groups.Results:The rates of symptom alleviated(93.4%)and pain alleviated(86.9%)of the patients in the experimental group after treatment were significantly higher than those(78.9% and 76.9%)of the patients in the control group.The menstrual recovery time(31.63.6d)of the patients in the experimental group was significantly shorter than that(37.4±4.9d)of the patients in the control group.The endometrial thickness(2.42±0.50cm)of the Patients in the experimental group was significantly lower than that(3.35±0.67cm)of the patients in the control group.The dysmenorrhea VAS score(2.57±1.21 points)of the patients in the experimental group was significantly lower than that(3.94±1.10 points)of the patients in the control group.The TNFa level(89.32±5.46 ng/L)of the patients in theexperimental group was significantly lowerthan that(107.83±8.19ng/L)of the patients in the control group.The levels of interleukin-2(73.21±7.15ng/L)and interleukin-10(94.719.86ng/L)ofthepatients in the experimental group were significantly higher than those(68.55±6.30ng/Land 88.55±8.18ng/L)of the patients in the control group.After treatment,the values of plasma viscosity,hematocrit,and e-rythrocyte sedimentation rate,and the levels of VEGF and CA125 of the patients in both groups had decreased signifi-cantly,and which of the patients in the experimental group were significantly lower than those of the patients in thecontrol group.The rates of EMS recurrence(6.6%)and the complication with infertility(8.2%)of the patients in theexperimental group were significantly lower than those(21.2%and 26.9%)of the patients in the control group(all P<0.05).There was no significant difference in the adverse reactions occurrence of the patients between the two groups(P>0.o5).Conclusion:Guizhi fuling capsule adjuvant treatment of the patients with EMS can promote their body recovery,improve their endometrial thickness and hemorheology,and regulate their inflammatory factors,with reliablesafety.